Dosing Complete in Phase 2 Trial Evaluating Lymfactin for BC Treatment-Associated Lymphedema

Dosing Complete in Phase 2 Trial Evaluating Lymfactin for BC Treatment-Associated Lymphedema
Herantis Pharma has completed patient dosing in its Phase 2 trial evaluating the investigational gene therapy Lymfactin for secondary lymphedema — a common complication of breast cancer treatment caused by the extensive removal of lymph nodes in the armpit region. The 39 patients included in the multicenter AdeLE trial (NCT03658967) — who were randomly assigned to receive Lymfactin or a placebo, given in combination with lymph node transplant surgery — will now be followed for one year to determine the treatment's safety and efficacy. Top-line results are expected in the first quarter of 2021. "The rapid enrolment completion demonstrates not only that there is a significant need for novel treatment options in lymphedema, but it is also an important milestone for our Lymfactin program as we are advancing into late-stage clinical development," Pekka Simula, CEO of Herantis Pharma, said in a press release. "We are truly grateful to the patients who participated in the AdeLE study, the supporting physicians and staff at the study sites, and to the international patient organization LE&RN, which fights to raise awareness for lymphedema as a
Subscribe or to access all post and page content.